S. Spies

发表

Association between African American race/ethnicity and low bone mineral density in women with systemic lupus erythematosus.

D. Dunlop, S. Manzi, R. Ramsey‐Goldman, 2007, Arthritis and rheumatism.

Staging and Monitoring of Small Cell Lung Cancer Using [18F]Fluoro-2-deoxy-D-glucose-Positron Emission Tomography (FDG-PET)

William Spies, Athanassios Argiris, A. Argiris, 2007, American journal of clinical oncology.

OctreoScan positive Crohn's disease mimicking an ileal carcinoid tumor.

F. Miller, A. Buchman, Jamie Marko, 2008, Journal of clinical gastroenterology.

Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation

A. Rademaker, L. Gordon, J. Winter, 2013, Leukemia & lymphoma.

Self-reported fractures and associated factors in women with systemic lupus erythematosus.

D. Dunlop, S. Manzi, R. Ramsey‐Goldman, 2007, The Journal of rheumatology.

Cancer Therapy : Clinical The Novel Expanded Porphyrin , Motexafin Gadolinium , Combined with [ 90 Y ] Ibritumomab Tiuxetan for Relapsed / Refractory Non-Hodgkin ' s Lymphoma : Preclinical Findings and Results of a Phase I Trial

L. Gordon, J. Winter, A. Evens, 2009 .

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

L. Gordon, J. Winter, A. Evens, 2009, Clinical Cancer Research.

Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non-Hodgkin's lymphoma.

B. B. Weitner, A. Rademaker, L. Gordon, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

L. Gordon, J. Murray, N. Bartlett, 2002, Blood.

Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma.

L. Gordon, M. Czuczman, I. Flinn, 2002, Seminars in oncology.

Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus.

A. Dyer, R. Ramsey‐Goldman, R. Pope, 2008, The Journal of rheumatology.

A Prospective Trial Comparing Lymphangiogram, Cross-Sectional Imaging, and Positron Emission Tomography Scan in the Detection of Lymph Node Metastasis in Locally Advanced Cervical Cancer

A. Rademaker, W. Small, A. Nemcek, 2010, American journal of clinical oncology.

Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids.

D. Dunlop, S. Manzi, R. Ramsey‐Goldman, 2006, Rheumatology.

90Y Ibritumomab Tiuxetan (Zevalin®; 90YZ) Doses Calculated To Deliver up to 1500 cGy to Critical Organs May Be Safely Combined with High-Dose BEAM and Autotransplant in NHL.

A. Rademaker, L. Gordon, J. Winter, 2006 .

Radioimmunotherapy of Relapsed Non-Hodgkin's Lymphoma with Zevalin, a 9~ Anti-CD20 Monoclonal Antibody 1

L. Gordon, D. Silverman, J. Gutheil, 1999 .

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.

L. Gordon, D. Silverman, J. Gutheil, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1.

A. M. Zimmer, T. Kuzel, S. Rosen, 1993, Cancer biotherapy.

Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

J A Parker, W D Erwin, D. Podoloff, 2001, Critical reviews in oncology/hematology.

Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.

L. Gordon, D. Silverman, J. Gutheil, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Radioimmunotherapy of patients with cutaneous T-cell lymphoma using an iodine-131-labeled monoclonal antibody: analysis of retreatment following plasmapheresis.

E. A. Silverstein, R. Goldman-Leikin, J. Kazikiewicz, 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.

L. Gordon, J. Murray, N. Bartlett, 2002, Blood.